{"id":"imiquimod-cream-surgery","safety":{"commonSideEffects":[{"rate":"40-90","effect":"Local skin irritation (erythema, erosion)"},{"rate":"20-50","effect":"Pruritus"},{"rate":"5-25","effect":"Systemic flu-like symptoms"},{"rate":"5-15","effect":"Lymphadenopathy"}]},"_chembl":{"chemblId":"CHEMBL1282","moleculeType":"Small molecule","molecularWeight":"240.31"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Imiquimod is a topical immune response modifier that binds to TLR7 and TLR8, triggering innate immune activation and promoting Th1 cytokine production at the application site. When combined with surgical excision, this approach aims to reduce recurrence by eliminating the lesion while enhancing local anti-tumor immunity. This combination strategy is being evaluated in phase 3 trials for skin cancer indications.","oneSentence":"Imiquimod cream activates toll-like receptors to stimulate local immune response, combined with surgical removal to treat skin lesions.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:15:34.729Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Basal cell carcinoma (adjuvant to surgery)"},{"name":"Cutaneous melanoma (adjuvant to surgery)"}]},"trialDetails":[{"nctId":"NCT03370406","phase":"PHASE1","title":"Intralesional 5-Fluorouracil (5FU), Topical Calcipotriene Treatment for SCC","status":"RECRUITING","sponsor":"Melissa Pugliano-Mauro","startDate":"2018-08-03","conditions":"Carcinoma, Squamous Cell","enrollment":30},{"nctId":"NCT02394132","phase":"PHASE3","title":"Radiotherapy or Imiquimod in Complex Lentigo Maligna","status":"COMPLETED","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2015-08-31","conditions":"Lentigo Maligna","enrollment":126},{"nctId":"NCT01720407","phase":"PHASE3","title":"Relevance of Imiquimod as Neo-adjuvant Treatment to Reduce Excision Size and the Risk of Intralesional Excision in Lentigo Malignant of the Face","status":"COMPLETED","sponsor":"Nantes University Hospital","startDate":"2012-12","conditions":"Lentigo Maligna Melanoma (Head or Neck)","enrollment":259},{"nctId":"NCT01808820","phase":"PHASE1","title":"Dendritic Cell (DC) Vaccine for Malignant Glioma and Glioblastoma","status":"COMPLETED","sponsor":"Macarena De La Fuente, MD","startDate":"2013-08-21","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":20},{"nctId":"NCT02242929","phase":"PHASE3","title":"Surgery Versus Combined Treatment With Curettage and Imiquimod for Nodular Basal Cell Carcinoma","status":"UNKNOWN","sponsor":"Maastricht University Medical Center","startDate":"2016-01","conditions":"Nodular Basal Cell Carcinoma","enrollment":145},{"nctId":"NCT01861535","phase":"PHASE3","title":"Primary Imiquimod Treatment Versus Surgery for Vulvar Intraepithelial Neoplasia","status":"COMPLETED","sponsor":"Medical University of Graz","startDate":"2013-06","conditions":"Vulvar Intraepithelial Neoplasia","enrollment":110},{"nctId":"NCT03760250","phase":"PHASE2","title":"Imiquimod for Preventing Keloid Recurrence","status":"TERMINATED","sponsor":"University of Pennsylvania","startDate":"2019-02-05","conditions":"Keloid","enrollment":6},{"nctId":"NCT03289260","phase":"PHASE3","title":"Adjuvant Anal Imiquimod Therapy in Anal HPV-lesions: AdAM-trial","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-11-15","conditions":"Anogenital Human Papillomavirus Infection, Condyloma Anal","enrollment":200},{"nctId":"NCT01088737","phase":"PHASE2, PHASE3","title":"Imiquimod to Detect Residual Lesions and Prevent Recurrence of Lentigo Maligna","status":"UNKNOWN","sponsor":"Medical University of Graz","startDate":"2011-01","conditions":"Lentigo Maligna","enrollment":60},{"nctId":"NCT02329171","phase":"PHASE3","title":"Imiquimod Treatment of CIN Lesions","status":"TERMINATED","sponsor":"Maastricht University Medical Center","startDate":"2014-12","conditions":"Cervical Intraepithelial Neoplasia","enrollment":9},{"nctId":"NCT00504023","phase":"NA","title":"Topical Imiquimod in Treating Patients With Recurrent Paget's Disease of the Vulva","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2007-04","conditions":"Vulvar Cancer","enrollment":8},{"nctId":"NCT02669459","phase":"PHASE3","title":"Imiquimod Treatment of Residual or Recurrent CIN Lesions: a Study Protocol","status":"UNKNOWN","sponsor":"Erasmus Medical Center","startDate":"2016-05","conditions":"Cervical Intraepithelial Neoplasia","enrollment":433},{"nctId":"NCT01792505","phase":"PHASE1","title":"Dendritic Cell Vaccine With Imiquimod for Patients With Malignant Glioma","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2009-10","conditions":"Malignant Glioma","enrollment":71},{"nctId":"NCT00066872","phase":"PHASE3","title":"Topical Imiquimod Compared With Surgery in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"Queen's Medical Center","startDate":"2002-10","conditions":"Non-melanomatous Skin Cancer","enrollment":500},{"nctId":"NCT00079300","phase":"PHASE1","title":"Imiquimod Cream in Treating Patients With Basal Cell Skin Cancer","status":"COMPLETED","sponsor":"National Naval Medical Center","startDate":"2004-01","conditions":"Non-melanomatous Skin Cancer","enrollment":""},{"nctId":"NCT00463359","phase":"NA","title":"A Pilot Study of the Treatment of Facial Nodular and Nodulocystic Basal Cell Carcinoma With Double Curettage and Cautery Followed by Application of Imiquimod to the Base","status":"UNKNOWN","sponsor":"University of Glasgow","startDate":"","conditions":"Basal Cell Carcinoma","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":171,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Imiquimod cream + surgery","genericName":"Imiquimod cream + surgery","companyName":"Nantes University Hospital","companyId":"nantes-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Imiquimod cream activates toll-like receptors to stimulate local immune response, combined with surgical removal to treat skin lesions. Used for Basal cell carcinoma (adjuvant to surgery), Cutaneous melanoma (adjuvant to surgery).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}